Entrada Therapeutics (NASDAQ:TRDA) Price Target Lowered to $18.00 at HC Wainwright

Entrada Therapeutics (NASDAQ:TRDA) had its price objective cut by HC Wainwright from $20.00 to $18.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Entrada Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.87) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.02) EPS and FY2025 earnings at ($3.77) EPS.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock opened at $14.25 on Tuesday. Entrada Therapeutics has a one year low of $10.75 and a one year high of $18.44. The company has a market cap of $481.07 million, a PE ratio of 22.62 and a beta of -0.23. The business has a 50-day simple moving average of $14.58 and a 200-day simple moving average of $14.30.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $1.06. Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%. The business had revenue of $59.12 million during the quarter, compared to the consensus estimate of $25.00 million. On average, sell-side analysts predict that Entrada Therapeutics will post -0.13 earnings per share for the current fiscal year.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, Director Peter S. Kim purchased 2,600 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was purchased at an average cost of $13.57 per share, with a total value of $35,282.00. Following the completion of the acquisition, the director now directly owns 62,936 shares of the company’s stock, valued at approximately $854,041.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Peter S. Kim acquired 2,600 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was acquired at an average cost of $13.57 per share, with a total value of $35,282.00. Following the completion of the acquisition, the director now owns 62,936 shares of the company’s stock, valued at $854,041.52. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Natarajan Sethuraman sold 9,675 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $15.19, for a total value of $146,963.25. Following the completion of the sale, the insider now directly owns 190,052 shares of the company’s stock, valued at $2,886,889.88. The disclosure for this sale can be found here. Insiders sold 13,475 shares of company stock valued at $205,133 over the last three months. 7.58% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the stock. New York State Teachers Retirement System purchased a new stake in shares of Entrada Therapeutics during the first quarter worth approximately $27,000. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics during the first quarter worth approximately $79,000. Tower Research Capital LLC TRC raised its stake in shares of Entrada Therapeutics by 476.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company’s stock worth $87,000 after purchasing an additional 4,777 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Entrada Therapeutics by 27.7% during the fourth quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock worth $177,000 after purchasing an additional 2,540 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Entrada Therapeutics by 427.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.